Table 1.
Patient characteristics
| Case | Age | Sex | Disease | Disease status at transplant |
1st donor |
HLA matching at A, B, DR allele |
CD34 stem cell dose (× 106/kg) |
Preparative regimen for the 1st transplantation |
Comment |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 39 | F | MF | NR | MUD | 6/6 | 4.51 | Flu/Bus/ATG | Failed the 2nd transplantation from a Haplo donor after Flu/Cy/Alem |
| 2 | 42 | M | AML | CR3 | Haplo | 3/6 | 20.0 | Flu/Bus/Alem | |
| 3 | 44 | F | AML | CR2 | Haplo | 4/6 | 12.8 | Flu/Bus/Alem | |
| 4 | 56 | M | CLL | PR | Haplo | 3/6 | 7.16 | Flu/Mel/Alem | ADV infection when graft failed |
| 5 | 67 | M | MF | NT | MUD | 6/6 | 8.03 | Flu/Bus/Alem | |
| 6 | 61 | F | MDS | NT | Haplo | 3/6 | 22.92 | Flu/Bus/Alem | |
| 7 | 28 | M | CML | CP2 | DUCB | 4/6 + 4/6 | 0.09 +0.09 | Flu/TBI | |
| 8 | 52 | M | AML | CR2 | DUCB | 4/6 + 4/6 | 0.16 +0.17 | Flu/TBI | |
| 9 | 28 | M | AML | CR2 | Haplo | 3/6 | 10.9 | Flu/Bus/Alem | |
| 10 | 59 | F | AML | CR1 | Haplo | 4/6 | 19.17 | Flu/Bus/Alem | Residual AML clones detected |
| 11 | 25 | M | AA | NT | MSD | 6/6 | 16.07 | Flu/Cy/Alem |
F, female; M, male; MF, myelofibrosis; AML, acute myelogenous leukemia; CLL, chronic lymphocytic leukemia; MDS, myelodysplastic syndrome; CML, chronic myelogenous leukemia; AA, aplastic anemia; NR, non-remission; CR, complete remission; PR, partial response; NT, no prior cytotoxic treatment; MUD, matched unrelated donor; Haplo, haploidentical related donor; DUCB, dual umbilical cord blood; MSD, matched sibling donor; RIC, reduced-intensity conditioning; MAC, myeloablative conditioning; Flu/Bus/ATG, fludarabine 160 mg/m2 + busulfan 520 mg/m2 + antithymocyte globulin 60 mg/kg; Flu/Bus/Alem, fludarabine 160 mg/m2 + busulfan 260 mg/m2 + alemtuzumab 80 mg; Flu/Mel/Alem, fludarabine 160mg/m2 + melphalan 140 mg/m2 + alemtuzumab 80 mg; Flu/TBI, fludarabine 160 mg/m2+ total-body irradiation 1350 cGy; Flu/Cy/Alem, fludarabine 120 mg/m2 + cyclophosphamide 2000 mg/m2 + alemtuzumab 100 mg; ADV, adenovirus.